Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Want to cut your energy bills? Here’s how five experts are doing it 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
BOSTON, March 01, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will make a corporate presentation and provide a business update at the 37th Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 8, 2017, at 8:00 a.m. ET.
A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
For more information about the conference, visit: www.cowen.com/conferences/upcoming-conferences.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]
Source: Albireo Pharma, Inc.
